ArticleJournal of vascular surgery. Venous and lymphatic disorders2020
Coagulopathy, thromboembolic complications, and the use of heparin in COVID-19 pneumonia.
Article in Journal of vascular surgery. Venous and lymphatic disorders, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Systematic review and meta-analysis of the prevalence of venous thromboembolic events in novel coronavirus disease-2019 patients.Journal of vascular surgery. Venous and lymphatic disorders · 2021Pooled it
- Age-driven shifts in T and NK cell responses amplify inflammation and coagulopathy during viral infection in mice and humans.Frontiers in immunology · 2026Article
- Control of tissue homeostasis by the extracellular matrix: Synthetic heparan sulfate as a promising therapeutic for periodontal health and bone regeneration.Periodontology 2000 · 2024Review
- Drugs for COVID-19: An Update.Molecules (Basel, Switzerland) · 2022Review
- The Role of Heparin in COVID-19: An Update after Two Years of Pandemics.Journal of clinical medicine · 2022Review
- Follow-up after acute thrombotic events following COVID-19 infection.Journal of vascular surgery · 2022Article
- Therapeutic approaches for SARS-CoV-2 infection.Methods (San Diego, Calif.) · 2021Review
- Occurrence, Fate, Effects, and Risks of Dexamethasone: Ecological Implications Post-COVID-19.International journal of environmental research and public health · 2021Review
- Inhaled Edoxaban dry powder inhaler formulations: Development, characterization and their effects on the coagulopathy associated with COVID-19 infection.International journal of pharmaceutics · 2021Article
- Heparin and Its Derivatives: Challenges and Advances in Therapeutic Biomolecules.International journal of molecular sciences · 2021Review
- COVID-19-associated venous thromboembolism portends worse survival.Seminars in vascular surgery · 2021Article
- Long-chain polyphosphates impair SARS-CoV-2 infection and replication.Science signaling · 2021Article
- Prophylactic heparin and risk of orotracheal intubation or death in patients with mild or moderate COVID-19 pneumonia.Scientific reports · 2021Article
- The Coronavirus Network Explorer: mining a large-scale knowledge graph for effects of SARS-CoV-2 on host cell function.BMC bioinformatics · 2021Article
- Management of therapeutic unfractionated heparin in COVID-19 patients: A retrospective cohort study.Research and practice in thrombosis and haemostasis · 2021Article
- A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor.Pharmacology & therapeutics · 2021Review
- Towards better understanding of the heparin role in NETosis: feasibility of using native mass spectrometry to monitor interactions of neutrophil elastase with heparin oligomers.International journal of mass spectrometry · 2021Article
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): a Systemic Infection.Clinical microbiology reviews · 2021Review
- SARS-CoV-2: Pathogenic Mechanisms and Host Immune Response.Advances in experimental medicine and biology · 2021Article
- A rapid review of recent advances in diagnosis, treatment and vaccination for COVID-19.AIMS public health · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The SARS-CoV-2 (COVID-19) is causing a pandemic and potentially fatal disease of global public health concern. Viral infections are known to be associated with coagulation impairment; thus, thrombosis, hemorrhage, or both may occur. Understanding the pathophysiologic mechanisms underlying the development of coagulation disorders during viral infection is essential for the development of therapeutic strategies. Coagulopathy in COVID-19 infection is emerging as a precipitant factor for severe respiratory complications and death. An increase in coagulation markers, such as fibrinogen and D-dimer, has been found in severe COVID-19 cases. Heparin, clinically used as an anticoagulant, also has anti-inflammatory properties, including binding of inflammatory cytokines, inhibition of neutrophil chemotaxis, and protection of endothelial cells, and a potential antiviral effect. We hypothesized that low-molecular-weight heparin may attenuate cytokine storm in COVID-19 patients; therefore, low-molecular-weight heparin could be a valid adjunctive therapeutic drug for the treatment of COVID-19 pneumopathy. In this paper, we review potential mechanisms involved in coagulation impairment after viral infection and the possible role of heparin in the treatment of COVID-19 patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.